Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *
                     Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
NEWS
         JAN 02
                 STN pricing information for 2008 now available
NEWS
         JAN 16
                 CAS patent coverage enhanced to include exemplified
                 prophetic substances
NEWS
     4 JAN 28
                 USPATFULL, USPAT2, and USPATOLD enhanced with new
                 custom IPC display formats
NEWS 5 JAN 28
                 MARPAT searching enhanced
NEWS 6 JAN 28
                 USGENE now provides USPTO sequence data within 3 days
                 of publication
NEWS 7 JAN 28
                 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                 U.S. National Patent Classification
NEWS 14 MAR 31
                 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                 IPC display formats
NEWS 15 MAR 31
                 CAS REGISTRY enhanced with additional experimental
                 spectra
NEWS 16 MAR 31
                 CA/CAplus and CASREACT patent number format for U.S.
                 applications updated
NEWS 17 MAR 31
                 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
                 STN AnaVist, Version 1, to be discontinued
NEWS 19 APR 04
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28
                 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
NEWS 24
         MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
NEWS 25
         JUN 06
                 EPFULL enhanced with 260,000 English abstracts
NEWS 26
         JUN 06
                 KOREAPAT updated with 41,000 documents
NEWS 27
                 USPATFULL and USPAT2 updated with 11-character
         JUN 13
                 patent numbers for U.S. applications
NEWS 28 JUN 19
                CAS REGISTRY includes selected substances from
                 web-based collections
```

NEWS 29 JUN 25 CA/CAplus and USPAT databases updated with IPC reclassification data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:28:11 ON 26 JUN 2008

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:28:41 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUN 2008 HIGHEST RN 1030702-50-1 DICTIONARY FILE UPDATES: 25 JUN 2008 HIGHEST RN 1030702-50-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\search2.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 17:32:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 83 TO ITERATE

100.0% PROCESSED 83 ITERATIONS 17 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1114 TO 2206 PROJECTED ANSWERS: 93 TO 587

L2 17 SEA SSS SAM L1

=> s 11 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y FULL SEARCH INITIATED 17:32:54 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 1708 TO ITERATE

100.0% PROCESSED 1708 ITERATIONS 277 ANSWERS

SEARCH TIME: 00.00.01

L3 277 SEA SSS FUL L1

 \Rightarrow s 13 and brown, w?/au

NUMERIC VALUE NOT VALID 'BROWN, W?'

0 BROWN, W?/AU

L4 0 L3 AND BROWN, W?/AU

=> file hcaplus

COST IN U.S. DOLLARS SINCE FILE

SINCE FILE TOTAL ENTRY SESSION 186.73 186.94

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 17:33:17 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2008 VOL 148 ISS 26 FILE LAST UPDATED: 25 Jun 2008 (20080625/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 L5 7 L3

=> s 15 and brown, w?/au 4240 BROWN, W?/AU L6 7 L5 AND BROWN, W?/AU

=> d 17, ibib abs hitstr, 1-7

L7 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

 \Rightarrow d 16, ibib abs hitstr, 1-7

L6 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:638846 HCAPLUS

DOCUMENT NUMBER: 143:153295

TITLE: Preparation of diarylmethylidenylpiperidines for the

management of pain

INVENTOR(S): Brown, William; Griffin, Andrew; Walpole,

Christopher

PATENT ASSIGNEE(S): Astrazeneca AB, Swed. SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE				
WO 2005066128	A1 20050721	WO 2005-SE13	20050105				
W: AE, AG, AL,	AM, AT, AU, AZ,	BA, BB, BG, BR, BW, 1	BY, BZ, CA, CH,				
CN, CO, CR,	CU, CZ, DE, DK,	DM, DZ, EC, EE, EG, 1	ES, FI, GB, GD,				
GE, GH, GM,	HR, HU, ID, IL,	IN, IS, JP, KE, KG, I	KP, KR, KZ, LC,				
LK, LR, LS,	LT, LU, LV, MA,	MD, MG, MK, MN, MW, I	MX, MZ, NA, NI,				
NO, NZ, OM,	PG, PH, PL, PT,	RO, RU, SC, SD, SE,	SG, SK, SL, SY,				
TJ, TM, TN,	TR, TT, TZ, UA,	UG, US, UZ, VC, VN,	YU, ZA, ZM, ZW				

```
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
                                20050721
                                            AU 2005-204009
     AU 2005204009
                         Α1
                                                                   20050105
     CA 2552850
                          Α1
                                20050721
                                            CA 2005-2552850
                                                                   20050105
     EP 1706380
                          Α1
                                20061004
                                            EP 2005-704687
                                                                   20050105
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
     CN 1926105
                         Α
                                20070307
                                           CN 2005-80006251
                                                                   20050105
     BR 2005006707
                         Α
                                20070502
                                            BR 2005-6707
                                                                   20050105
     JP 2007517872
                         Τ
                                20070705
                                            JP 2006-549189
                                                                   20050105
     IN 2006DN03735
                                20070420
                                            IN 2006-DN3735
                         Α
                                                                   20060629
     MX 2006PA07662
                                20060904
                                            MX 2006-PA7662
                                                                   20060703
                         Α
     NO 2006003617
                                            NO 2006-3617
                         Α
                                20061009
                                                                   20060809
PRIORITY APPLN. INFO.:
                                            SE 2004-25
                                                                A 20040109
                                                                W 20050105
                                            WO 2005-SE13
                    CASREACT 143:153295; MARPAT 143:153295
OTHER SOURCE(S):
GΙ
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
AB
     Title compds. I [R1 = (un)substituted aryl, heteroaryl; R2 = alkyl, H; R3
     = H, COR4, SO2R4, etc.; R4 = H, alkyl, alkenyl, etc.] and their
     pharmaceutically acceptable salts were prepared For example, N-acetylation
     of aniline II (R2 = H) with acetic anhydride afforded the TFA salt of
     diarylmethylidenylpiperidine II (R2 = COCH3) in 100% yield. In human
     \delta receptor assays, certain examples of compds. I exhibited IC50
     values ranging from 0.22-2.34 nM, with an average of 0.98 nM (sic).
ΤТ
     859911-40-3P, 4-[[4-(Acetylamino)phenyl](1-benzylpiperidin-4-
     ylidene)methyl]-N, N-diethylbenzamide 859911-41-4P
     859911-42-5P, 4-[[4-(Acetylamino)phenyl][1-(pyridin-2-
     ylmethyl)piperidin-4-ylidene]methyl]-N, N-diethylbenzamide
     859911-43-6P 859911-44-7P 859911-45-8P
     859911-46-9P 859911-47-0P 859911-48-1P,
     4-[[4-(Acetylamino)phenyl][1-(1,3-thiazol-4-ylmethyl)piperidin-4-
     ylidene]methyl]-N, N-diethylbenzamide 859911-49-2P
     859911-50-5P, 4-[(1-Benzylpiperidin-4-ylidene)[4-
     [(methylsulfonyl)amino]phenyl]methyl]-N, N-diethylbenzamide
     859911-51-6P 859911-52-7P 859911-53-8P
     859911-54-9P, 4-[[4-(Acetylamino)phenyl][1-(2-
     fluorobenzyl)piperidin-4-ylidene]methyl]-N, N-diethylbenzamide
     859911-55-0P 859911-56-1P 859911-57-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of diarylmethylidenylpiperidines for the management of pain)
```

Benzamide, 4-[[4-(acetylamino)phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

RN

859911-40-3 HCAPLUS

RN 859911-41-4 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 859911-40-3 CMF C32 H37 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-42-5 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-43-6 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 859911-42-5 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-44-7 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-45-8 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-46-9 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(1,2,3-thiadiazol-5-ylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-47-0 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-48-1 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-49-2 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 859911-48-1 CMF C29 H34 N4 O2 S

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-50-5 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[4-[(methylsulfonyl)amino]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

RN 859911-51-6 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[4-[(methylsulfonyl)amino]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 859911-50-5 CMF C31 H37 N3 O3 S

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-52-7 HCAPLUS

CN Carbamic acid, [4-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-53-8 HCAPLUS

CN Carbamic acid, [4-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-52-7 CMF C32 H37 N3 O3

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-54-9 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-[(2-fluorophenyl)methyl]-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-55-0 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-[(2-fluorophenyl)methyl]-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 859911-54-9 CMF C32 H36 F N3 O2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-56-1 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-[(3-fluorophenyl)methyl]-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 859911-57-2 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl][1-[(4-fluorophenyl)methyl]-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)


IT 859911-59-4P, 4-[[4-(Acetylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethylbenzamide 859911-61-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diarylmethylidenylpiperidines for the management of pain)


RN 859911-59-4 HCAPLUS

CN Benzamide, 4-[[4-(acetylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)



RN 859911-61-8 HCAPLUS

CN Carbamic acid, [4-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:638845 HCAPLUS

DOCUMENT NUMBER: 143:153294

TITLE: Preparation of diarylmethylidenylpiperidines for the

management of pain

INVENTOR(S): Brown, William; Griffin, Andrew

PATENT ASSIGNEE(S): Astrazeneca AB, Swed. SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICAT	DATE			
WO 20050661	.27	A1	20050721	WO 2005-	20050105			
W: AE,	AG, AL	, AM, AI	, AU, AZ,	BA, BB, BG,	BR, BW, BY	, BZ, CA, CH,		
CN,	CO, CR	, CU, CZ	, DE, DK,	DM, DZ, EC,	EE, EG, ES	, FI, GB, GD,		
GE,	GH, GM	, HR, HU	, ID, IL,	IN, IS, JP,	KE, KG, KP	, KR, KZ, LC,		
LK,	LR, LS	, LT, LU	, LV, MA,	MD, MG, MK,	MN, MW, MX	, MZ, NA, NI,		
NO,	NZ, OM	, PG, PH	, PL, PT,	RO, RU, SC,	SD, SE, SG	, SK, SL, SY,		

```
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
            RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
            MR, NE, SN, TD, TG
                                          AU 2005-204008
    AU 2005204008
                         Α1
                               20050721
                                                                  20050105
    AU 2005204008
                         В2
                               20080424
    CA 2552946
                         Α1
                               20050721
                                           CA 2005-2552946
                                                                  20050105
                               20061004
                                           EP 2005-704686
    EP 1706379
                         Α1
                                                                  20050105
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
    CN 1926106
                               20070307
                                          CN 2005-80006331
                                                                  20050105
                         Α
                               20070502
    BR 2005006695
                                           BR 2005-6695
                         Α
                                                                  20050105
    JP 2007517871
                               20070705
                                           JP 2006-549188
                         Τ
                                                                  20050105
    IN 2006DN03740
                               20070420
                                           IN 2006-DN3740
                         Α
                                                                  20060629
    MX 2006PA07663
                                           MX 2006-PA7663
                         Α
                               20060904
                                                                  20060703
    NO 2006003618
                               20061009
                                           NO 2006-3618
                                                                  20060809
                         Α
    US 20070219249
                         Α1
                               20070920
                                           US 2006-596850
                                                                  20061208
PRIORITY APPLN. INFO.:
                                           SE 2004-26
                                                               A 20040109
                                                               W 20050105
                                           WO 2005-SE12
                  CASREACT 143:153294; MARPAT 143:153294
OTHER SOURCE(S):
```

```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
```

```
AB Title compds. I [R1, R3 = H, alkyl, cycloalkyl, etc.; R2 = alkyl, alkenyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, N-alkylation of piperidine II (R2 = H) with 1-iodopropane afforded the TFA salt of diarylmethylidenylpiperidine II (R2 = CH2CH2CH3) in 54% yield. In human \delta receptor assays, certain examples of compds. I exhibited IC50 values ranging from 0.18-3.7 nM, with an average of 0.56 nM (sic).  
IT 859911-03-8P 859911-04-9P 859911-05-0P 859911-06-1P 859911-07-2P 859911-08-3P
```

859911-09-4P 859911-10-7P 859911-11-8P 859911-12-9P 859911-13-0P 859911-14-1P 859911-15-2P 859911-16-3P 859911-17-4P

859911-15-2P 859911-16-3P 859911-17-4P 859911-18-5P 859911-19-6P 859911-20-9P

859911-21-0P 859911-22-1P 859911-23-2P 859911-24-3P 859911-25-4P 859911-26-5P

859911-27-6P 859911-28-7P 859911-29-8P 859911-30-1P 859911-31-2P 859911-32-3P

859911-33-4P 859911-34-5P 859911-35-6P,

[3-[[4-[(Diethylamino)carbonyl]phenyl][1-(2-methoxyethyl)-4-piperidinylidene]methyl]phenyl]carbamic acid methyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylmethylidenylpiperidines for the management of pain) RN 859911-03-8 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-propyl-4-piperidinylidene)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-04-9 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-propyl-4-piperidinylidene)methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-03-8 CMF C28 H37 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-05-0 HCAPLUS

CN Carbamic acid, [3-[[1-(cyclopropylmethyl)-4-piperidinylidene][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-06-1 HCAPLUS

CN Carbamic acid, [3-[[1-(cyclopropylmethyl)-4-piperidinylidene][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-05-0 CMF C29 H37 N3 O3

CM 2

RN 859911-07-2 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-pentyl-4-piperidinylidene)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-08-3 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-pentyl-4-piperidinylidene)methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-07-2 CMF C30 H41 N3 O3

CM 2

RN 859911-09-4 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-propyl-4-piperidinylidene)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\$$

RN 859911-10-7 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-propyl-4-piperidinylidene)methyl]phenyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-09-4 CMF C29 H39 N3 O3

CM 2

RN 859911-11-8 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-methoxyethyl)-4-piperidinylidene]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 859911-12-9 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(2-methoxyethyl)-4piperidinylidene]methyl]phenyl]-, ethyl ester, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 859911-11-8 CMF C29 H39 N3 O4

$$\begin{array}{c|c} \text{MeO-CH}_2-\text{CH}_2\\ \hline \\ \text{N} & \text{O}\\ \hline \\ \text{EtO-C-NH} & \text{C-NEt}_2\\ \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-13-0 HCAPLUS

CN Carbamic acid, [3-[(1-butyl-4-piperidinylidene)[4-

[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 859911-14-1 HCAPLUS

CM 1

CRN 859911-13-0 CMF C30 H41 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-15-2 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-[2-(1-methylethoxy)ethyl]-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI)

(CA INDEX NAME)

RN 859911-16-3 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-[2-(1-methylethoxy)ethyl]-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-15-2 CMF C30 H41 N3 O4

$$\begin{array}{c|c} \text{i-PrO-CH}_2-\text{CH}_2\\ \\ \text{N} \\ \text{O}\\ \\ \text{MeO-C-NH}\\ \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-17-4 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(2-ethoxyethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-18-5 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(2-ethoxyethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-17-4 CMF C29 H39 N3 O4

$$\begin{array}{c|c} \text{EtO-CH}_2\text{-CH}_2\\ \hline \\ N\\ \text{C}\\ \hline \\ NH-C-OMe\\ \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-19-6 HCAPLUS CN Carbamic acid, [3-[(1-butyl-4-piperidinylidene)[4[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & n-Bu \\ & & \\ N \\ \hline \\ NH-C-OMe \\ \\ O \\ \end{array}$$

● HCl

RN 859911-20-9 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(3-methoxypropyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 859911-21-0 HCAPLUS

CN Carbamic acid, [3-[[1-(cyclobutylmethyl)-4-piperidinylidene][4[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA
INDEX NAME)

10533838

RN 859911-22-1 HCAPLUS

CN Carbamic acid, [3-[[1-(cyclobutylmethyl)-4-piperidinylidene][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-21-0 CMF C30 H39 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-23-2 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-methyl-4-piperidinylidene)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)


10533838

RN 859911-24-3 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-methyl-4-piperidinylidene)methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-23-2 CMF C26 H33 N3 O3



CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-25-4 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-ethyl-4-piperidinylidene)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-26-5 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-ethyl-4-piperidinylidene)methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-25-4 CMF C27 H35 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-27-6 HCAPLUS

CN Carbamic acid, [3-[[1-(cyclopropylmethyl)-4-piperidinylidene][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA

INDEX NAME)

RN 859911-28-7 HCAPLUS

CN Carbamic acid, [3-[[1-(cyclopropylmethyl)-4-piperidinylidene][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-27-6 CMF C30 H39 N3 O3

CM 2

RN 859911-29-8 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-methyl-4-piperidinylidene)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ & \\ & \\ N \\ \text{NH-C-OEt} \\ \\ \text{O} \\ \end{array}$$

RN 859911-30-1 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-methyl-4-piperidinylidene)methyl]phenyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-29-8 CMF C27 H35 N3 O3

CM 2

RN 859911-31-2 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-ethyl-4-piperidinylidene)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 859911-32-3 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl](1-ethyl-4-piperidinylidene)methyl]phenyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859911-31-2 CMF C28 H37 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 859911-33-4 HCAPLUS

CN Carbamic acid, [3-[(1-butyl-4-piperidinylidene)[4-

[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & n-Bu \\ & & \\ N \\ \hline \\ NH-C-OMe \\ \\ O \\ \end{array}$$

RN 859911-34-5 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(3-methoxypropyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 859911-35-6 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(2-methoxyethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

IT 725229-85-6P 859911-38-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diarylmethylidenylpiperidines for the management of pain)

RN 725229-85-6 HCAPLUS


CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]-4-

piperidinylidenemethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 859911-38-9 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1016017 HCAPLUS

DOCUMENT NUMBER: 142:6430

TITLE: Preparation of diarylmethylidene piperidine

derivatives as opioid $\boldsymbol{\delta}$ receptor ligands for

treating pain, anxiety and functional gastrointestinal

disorders

INVENTOR(S): Brown, William L.; Griffin, Andrew; Jin,

Shujuan

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

10533838

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

								APPLICATION NO.										
								WO 2004-GB2074										
	W:						ΑU,											
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,	
			,	,	,	,	LV,			,	,	,	,	,	,			
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW	
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	
		ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	${ m ML}$,	MR,	ΝE,	
		•	TD,															
AU	2004	2386	18					AU 2004-238618					20040513					
							CA 2004-2525860											
EP	2 1641757						EP 2004-732665											
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,	
					•		RO,											HR
BR 2004010347			Α	20060530			BR 2004-10347				20040513							
CN 1823040			А	A 20060823		CN 2004-80020330				20040513								
JP	2007	5034	57		T 20070222					20040513								
					A 20071221		IN 2005-DN4901											
								US 2005-555980										
					A 20060208													
NO 2005005998				Α	A 20060213			NO 2005-5998 SE 2003-1444										
ORITY APPLN. INFO.		.:																
															A 2			
										WO 2	004-	GB20	74	1	W 2	0040	513	
FD SC	TIDCE	191.			MADI	ד ע כ	1/12 •	6/13/1										

OTHER SOURCE(S): MARPAT 142:6430

GI

AB The title compds. [I; R1 = H, (un)substituted alkyl, aryl, etc.; R2-R4 = H, (un)substituted alkyl, cycloalkyl; R7 = H, OH, alkyl, etc.] which are useful in therapy, in particular in the management of pain, were prepared

Ι

ΤT

E.g., a multi-step synthesis of I [R1 = H; R2, R3 = Et; R4 = COPh; R7 = H], starting from Me 4-(bromomethyl)benzoate, was given. The compds. I were found to be active toward human δ receptors. Generally, for most of the compds. I the IC50 values are in the range of 0.48 nM to 17.9 nM. The pharmaceutical composition comprising the compound I is disclosed. 798549-77-6P 798549-78-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diarylmethylidene piperidine derivs. as opioid δ receptor ligands for treating pain, anxiety and functional gastrointestinal disorders)

RN 798549-77-6 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-78-7 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

IT 798549-16-3P 798549-17-4P 798549-18-5P 798549-19-6P 798549-21-0P 798549-22-1P 798549-23-2P 798549-24-3P 798549-25-4P 798549-26-5P 798549-27-6P 798549-28-7P 798549-29-8P 798549-30-1P 798549-31-2P 798549-32-3P 798549-35-6P 798549-36-7P 798549-39-0P 798549-40-3P 798549-41-4P 798549-42-5P 798549-43-6P 798549-44-7P

RN

CN

```
798549-45-8P 798549-46-9P 798549-47-0P
798549-48-1P 798549-49-2P 798549-50-5P
798549-51-6P 798549-52-7P 798549-53-8P
798549-54-9P 798549-59-4P 798549-60-7P
798549-67-4P 798549-68-5P 798549-69-6P
798549-70-9P 798549-71-0P 798549-72-1P
798549-73-2P 798549-74-3P 798549-79-8P
798549-80-1P 798549-81-2P 798549-82-3P
798549-85-6P 798549-86-7P 798549-87-8P
798549-88-9P 798549-89-0P 798549-90-3P
798549-91-4P 798549-92-5P 798549-97-0P
798549-98-1P 798549-99-2P 798550-00-2P
798550-01-3P 798550-02-4P 798550-03-5P
798550-04-6P 798550-05-7P 798550-06-8P
798550-07-9P 798550-08-0P 798550-09-1P
798550-10-4P 798550-11-5P 798550-12-6P
798550-13-7P 798550-14-8P 798550-15-9P
798550-16-0P 798550-17-1P 798550-31-9P
798550-32-0P 798550-33-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (preparation of diarylmethylidene piperidine derivs. as opioid \delta
   receptor ligands for treating pain, anxiety and functional
   gastrointestinal disorders)
798549-16-3 HCAPLUS
Benzamide, 4-[[2-(benzoylamino)phenyl]-4-piperidinylidenemethyl]-N,N-
diethyl- (CA INDEX NAME)
```

RN 798549-17-4 HCAPLUS
CN Benzamide, 4-[[2-(benzoylamino)phenyl]-4-piperidinylidenemethyl]-N,Ndiethyl-, 2,2,2-trifluoroacetate (5:6) (CA INDEX NAME)

CM 1

CRN 798549-16-3 CMF C30 H33 N3 O2 10533838

$$\begin{array}{c|c} & & & & & \\ & & & & \\ Et_2N-C & & & Ph-C-NH \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-18-5 HCAPLUS

CN Benzeneacetamide, N-[2-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Ph} & \text{O} \\ & \text{CH}_2\text{--}\text{C} \\ & \text{NH} \\ & \text{NH} \\ & \text{H} \end{array}$$

RN 798549-19-6 HCAPLUS

CN Benzeneacetamide, N-[2-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 798549-18-5 CMF C31 H35 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-21-0 HCAPLUS

CN Benzamide, 4-[[2-[(cyclohexylcarbonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-22-1 HCAPLUS

CN Benzamide, 4-[[2-[(cyclohexylcarbonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 798549-21-0 CMF C30 H39 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-23-2 HCAPLUS

CN Benzenepropanamide, N-[2-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} \text{Ph-CH}_2\text{-CH}_2\text{-C} \\ \\ 0 \\ \\ \text{Et}_2\text{N-C} \\ \end{array}$$

RN 798549-24-3 HCAPLUS

CN Benzenepropanamide, N-[2-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 798549-23-2 CMF C32 H37 N3 O2

$$\begin{array}{c|c} \text{Ph-CH}_2\text{-CH}_2\text{-C} \\ \text{O} \\ \text{Et}_2\text{N-C} \\ \text{NH} \\ \text{H} \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-25-4 HCAPLUS

CN Benzamide, 4-[[2-[(2-cyclohexylacetyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-26-5 HCAPLUS

CN Benzamide, 4-[[2-[(2-cyclohexylacetyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 798549-25-4 CMF C31 H41 N3 O2

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

CM 2

RN 798549-27-6 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[(2-phenylethyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\mathsf{Et}_2 \mathsf{N} - \mathsf{C}$$

RN 798549-28-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[(2-phenylethyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:6) (CA INDEX NAME)

CM 1

CRN 798549-27-6 CMF C31 H37 N3 O

$$\mathsf{Et}_2\mathsf{N}-\mathsf{C}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-29-8 HCAPLUS

CN Benzamide, 4-[[2-[(cyclohexylmethyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-30-1 HCAPLUS

CN Benzamide, 4-[[2-[(cyclohexylmethyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CRN 798549-29-8 CMF C30 H41 N3 O

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-31-2 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[(phenylmethyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 798549-32-3 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[(phenylmethyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CRN 798549-31-2 CMF C30 H35 N3 O

$$\begin{array}{c|c} \mathsf{C} & \mathsf{Ph-CH}_2-\mathsf{NH} \\ & \mathsf{C} & \mathsf{Ph-CH}_2-\mathsf{NH} \\ & \mathsf{C} & \mathsf{NH} \\ & \mathsf{NH} & \mathsf{H} \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-35-6 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[[(phenylamino)carbonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 798549-36-7 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[[(phenylamino)carbonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:19) (CA INDEX NAME)

CRN 798549-35-6 CMF C30 H34 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-39-0 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-(methylphenylamino)phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 798549-40-3 HCAPLUS

ON Benzamide, N,N-diethyl-4-[[2-(methylphenylamino)phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 798549-39-0 CMF C30 H35 N3 O

$$\begin{array}{c|c} O & Ph \\ \parallel & \parallel \\ \text{Et}_2N-C & \text{Me-}N \\ \hline & C \\ \hline & N \\ H \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-41-4 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[(phenylsulfonyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 798549-42-5 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[(phenylsulfonyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 798549-41-4 CMF C29 H33 N3 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-43-6 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[[(phenylmethyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & H \\ & & & \\ & & & \\ Et_2N-C & & & \\ & &$$

RN 798549-44-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[[(phenylmethyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CRN 798549-43-6 CMF C30 H35 N3 O3 S

$$\begin{array}{c|c} & & & H \\ & & & \\ & & \\ Et_2N-C & & \\ &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-45-8 HCAPLUS

CN Benzamide, N, N-diethyl-4-[4-piperidinylidene[2-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl]methyl]- (CA INDEX NAME)

RN 798549-46-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[4-piperidinylidene[2-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl]methyl]-, 2,2,2-trifluoroacetate

(1:1) (CA INDEX NAME)

CM 1

CRN 798549-45-8 CMF C25 H30 F3 N3 O3 S

$$\begin{array}{c|c} F_3C-CH_2 \\ \hline 0 \\ \hline 0 \\ \hline S \\ \hline 0 \\ \hline NH \\ H \\ \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-47-0 HCAPLUS

CN Benzamide, 4-[[2-[(2-cyclopentylacetyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & \\ & & \\ & & \\ & \\ & \\ & & \\ & \\ & & \\ & \\ & & \\ & \\ & \\ & & \\ & \\ & \\ & & \\ & \\ & &$$

RN 798549-48-1 HCAPLUS

CN Benzamide, 4-[[2-[(2-cyclopentylacetyl)amino]phenyl]-4piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:11) (CA
INDEX NAME)

CM 1

CRN 798549-47-0 CMF C30 H39 N3 O2

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-49-2 HCAPLUS

CN Benzamide, 4-[[2-[(cyclopentylcarbonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-50-5 HCAPLUS

CN Benzamide, 4-[[2-[(cyclopentylcarbonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 798549-49-2 CMF C29 H37 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-51-6 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[(3-phenylpropyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 798549-52-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[(3-phenylpropyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:9) (CA INDEX NAME)

CM 1

CRN 798549-51-6 CMF C32 H39 N3 O

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-53-8 HCAPLUS

CN Benzamide, 4-[[2-[(2-cyclohexylethyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

CMF

RN 798549-54-9 HCAPLUS
CN Benzamide, 4-[[2-[(2-cyclohexylethyl)amino]phenyl]-4 piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:13) (CA
 INDEX NAME)
CM 1
CRN 798549-53-8

C31 H43 N3 O

CM 2
CRN 76-05-1
CMF C2 H F3 O2

RN 798549-59-4 HCAPLUS
CN Benzamide, N,N-diethyl-4-[[2-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 798549-60-7 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[2-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:6) (CA INDEX NAME)

CM 1

CRN 798549-59-4 CMF C31 H36 N4 O2

CM 2

RN 798549-67-4 HCAPLUS

CN Benzamide, 4-[[2-(cyclohexylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ & & \\$$

RN 798549-68-5 HCAPLUS

CN Benzamide, 4-[[2-(cyclohexylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

CM 1

CRN 798549-67-4 CMF C30 H41 N3 O

$$\begin{array}{c|c} & \text{Me} \\ & & \\$$

CM 2

RN 798549-69-6 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[[(4-methylphenyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} \\ \hline \\ \text{O} & \text{S} \\ \hline \\ \text{O} & \text{S} \\ \hline \\ \text{NH} \\ \\ \\ \text{H} \end{array}$$

RN 798549-70-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[[(4-methylphenyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 798549-69-6 CMF C30 H35 N3 O3 S

CM 2

RN 798549-71-0 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[[(2-fluorophenyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

RN 798549-72-1 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-[[(2-fluorophenyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:6) (CA INDEX NAME)

CM 1

CRN 798549-71-0

CMF C29 H32 F N3 O3 S

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-73-2 HCAPLUS

CN Benzamide, 4-[[2-[(butylsulfonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & & & H \\ & & & \\ & &$$

RN 798549-74-3 HCAPLUS

CN Benzamide, 4-[[2-[(butylsulfonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 798549-73-2 CMF C27 H37 N3 O3 S

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-79-8 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-80-1 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:17) (CA INDEX NAME)

CM 1

CRN 798549-79-8 CMF C32 H37 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-81-2 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} C & O & O \\ \parallel & \parallel & \parallel \\ \text{MeO-C-NH} \\ \hline \\ C & \\ \hline \\ Ph-CH_2 \end{array}$$

RN 798549-82-3 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 798549-81-2 CMF C32 H37 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-85-6 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-86-7 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CRN 798549-85-6 CMF C29 H34 N4 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-87-8 HCAPLUS
CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 798549-88-9 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 798549-87-8 CMF C29 H34 N4 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-89-0 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-90-3 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:19) (CA INDEX NAME)

CM 1

CRN 798549-89-0 CMF C29 H34 N4 O2 S

CM 2

RN 798549-92-5 HCAPLUS
CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 798549-91-4 CMF C29 H34 N4 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798549-97-0 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-98-1 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798549-99-2 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (2:7) (CA INDEX NAME)

CM 1

CRN 798549-98-1 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-00-2 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl](1-butyl-4-piperidinylidene)methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798550-01-3 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl](1-butyl-4-piperidinylidene)methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 798550-00-2 CMF C29 H39 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-02-4 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(2-pyridinylmethyl)-4-

piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798550-03-5 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 798550-02-4 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-04-6 HCAPLUS

CN Carbamic acid, [2-[(1-butyl-4-piperidinylidene)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 798550-05-7 HCAPLUS

CN Carbamic acid, [2-[(1-butyl-4-piperidinylidene)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:27) (9CI) (CA INDEX NAME)

CM 1

CRN 798550-04-6 CMF C29 H39 N3 O3

CM 2

RN 798550-06-8 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 798550-07-9 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 798550-08-0 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl][1-(3-

pyridinylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 798550-07-9 CMF C31 H36 N4 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-09-1 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

10533838

RN 798550-10-4 HCAPLUS

CN Benzamide, 4-[(1-butyl-4-piperidinylidene)[2-(ethylamino)phenyl]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 798550-11-5 HCAPLUS

CN Benzamide, 4-[(1-butyl-4-piperidinylidene)[2-(ethylamino)phenyl]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 798550-10-4 CMF C29 H41 N3 O 10533838

CM 2

CRN 76-05-1 CMF C2 H F3 O2

$$\begin{array}{c} F \\ | \\ F - C - CO_2H \\ | \\ F \end{array}$$

RN 798550-12-6 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-(ethylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

RN 798550-13-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-(ethylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (10:23) (CA INDEX NAME)

CM 1

CRN 798550-12-6 CMF C31 H38 N4 O

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-14-8 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-(ethylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

RN 798550-15-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-(ethylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (10:23) (CA INDEX NAME)

CM 1

CRN 798550-14-8 CMF C31 H38 N4 O

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-16-0 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-(ethylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

RN 798550-17-1 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[2-(ethylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 798550-16-0 CMF C31 H38 N4 O

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-31-9 HCAPLUS

CN Benzamide, 4-[[2-(acetylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 798549-97-0 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2 10533838

RN 798550-32-0 HCAPLUS

CN Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl]][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, trifluoroacetate (5:11) (9CI) (CA INDEX NAME)

CM 1

CRN 798550-06-8 CMF C31 H36 N4 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 798550-33-1 HCAPLUS

Carbamic acid, [2-[[4-[(diethylamino)carbonyl]phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester,

trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 798550-09-1 CMF C31 H36 N4 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610034 HCAPLUS

DOCUMENT NUMBER: 141:140326

TITLE: Preparation of diarylmethylidene piperidines as

 δ -opioid receptor ligands for the treatment of

pain.

INVENTOR(S): Brown, William; Griffin, Andrew; Walpole,

Christopher

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

								APPLICATION NO.												
WO	2004062562				A2 20040729				WO	20	04-		20040113							
WO	2004062562				A3 20040916															
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BE	3,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,		
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	D2	Ζ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,		
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	ΙS	3,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,		
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MO	∃,	MK,	MN,	MW,	MX,	MZ				
AU	2004	2043	90		A1 20040729					ΑU	20	004-								
AU	2004	2043	90		В2		2007	0906												
CA	2510			A1 20040729					CA	20	004-		20040113							
EP					A2		2005	EP 2004-701624							2	0040	040113			
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	٦,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,		
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑI	J,	TR,	BG,	CZ,	EE,	HU,	SK			
BR	2004006614			Α	BR 2004-6614 CN 2004-80002275 JP 2006-500202							2	0040	113						
CN	1738801			A 20060222					CN	20	004-	8000		2	0040	113				
JP	2006	5165	59		T		JΡ	20	06-	5002	20040113									
NZ	5407	758			A 20080328					NZ	20	004-	5407	20040113						
RU	2324	1680			C2		0520	NZ 2004-540758 RU 2005-121491							20040113					
IN	2005	DN02	714		Α		2007	0112		IN					20050620					
ZA	2005	0051	86		Α		2006	0426					5186			0050				
							2006			US	20	05-	5415.	22		2	0050	707		
MX	2005	PA07	484		Α		2005	0921		MX	20	05-	PA74	84		2	0050	711		
							2005			ИО	20	05-	3809			2	0050	812		
PRIORIT	RIORITY APPLN. INFO.:									SE	20	003-	105			A 2	0030	116		
																	0040			
OTHER SO	THER SOURCE(S):					PAT	141:	14032												

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [R1 = (un)substituted aryl, heteroaryl; R2, R3, R4, R5 = H, alkyl, cycloalkyl] and their pharmaceutically acceptable salts were prepared For example, acylation of aniline II [R6 = H], e.g., prepared from 4-(bromomethyl)benzoic acid Me ester in 8-steps, with acetyl chloride afforded piperidine II [R6 = COMe] as the trifluoroacetic acid salt in 52% yield. In human δ -opioid receptor binding assays, 7-examples of compds. I exhibited IC50 values ranging from 0.19-1.49 nM. Compds. I are claimed useful in the management of pain.
- TT 725242-56-8P, 4-[[3-(Acetylamino)phenyl][1-(thien-2ylmethyl)piperidin-4-ylidene]methyl]-N,N-diethylbenzamide
 725242-57-9P, 4-[[3-(Acetylamino)phenyl][1-(2furylmethyl)piperidin-4-ylidene]methyl]-N,N-diethylbenzamide
 725242-58-0P, 4-[[3-(Acetylamino)phenyl][1-(phenylmethyl)-4piperidinylidene]methyl]-N,N-diethylbenzamide 725242-59-1P,
 4-[[3-(Acetylamino)phenyl][1-(3-thienylmethyl)-4-piperidinylidene]methyl]N,N-diethylbenzamide 725242-60-4P, 4-[[3-(Acetylamino)phenyl][1-

(3-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethylbenzamide 725242-61-5P, 4-[[3-(Acetylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethylbenzamide 725242-62-6P, 4-[[3-(Acetylamino)phenyl][1-(pyridin-2-ylmethyl)piperidin-4-ylidene]methyl]-N,N-diethylbenzamide 725242-63-7P, 4-[[3-(Acetylamino)phenyl][1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl]-N,N-diethylbenzamide 725242-64-8P, 4-[[3-(Acetylamino)phenyl][1-(1,3-thiazol-5-ylmethyl)piperidin-4-ylidene]methyl]-N,N-diethylbenzamide 725242-67-1P 725242-70-6P 725242-71-7P 725242-75-1P 725242-80-8P 725242-83-1P 725242-87-5P 725242-88-6P 725242-90-0P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of diarylmethylidene piperidines as δ -opioid receptor

ligands for the treatment of pain.) RN 725242-56-8 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-57-9 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(2-furanylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-58-0 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-59-1 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(3-thienylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-60-4 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-61-5 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-62-6 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-63-7 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-64-8 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl- (CA INDEX NAME)

RN 725242-67-1 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-56-8 CMF C30 H35 N3 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-70-6 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(2-furanylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-57-9 CMF C30 H35 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-71-7 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-58-0 CMF C32 H37 N3 O2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-75-1 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(3-thienylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

RN 725242-80-8 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-60-4 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-83-1 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(4-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-61-5 CMF C31 H36 N4 O2 10533838

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-87-5 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(2-pyridinylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-62-6 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-88-6 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-63-7 CMF C29 H34 N4 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 725242-90-0 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 725242-64-8

CMF C29 H34 N4 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

TT 725242-85-3P, 4-[[3-(Acetylamino)phenyl](piperidin-4ylidene)methyl]-N,N-diethylbenzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of diarylmethylidene piperidines as $\delta\text{-opioid}$ receptor ligands for the treatment of pain.)

RN 725242-85-3 HCAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

L6 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:606467 HCAPLUS

DOCUMENT NUMBER: 141:157038

TITLE: Preparation of 4-[3-(sulfonylamino)phenyl-1-(cyclymethyl)piperidin-4-ylidenemethyl]benazmide

derivatives as delta opioid receptor ligands

INVENTOR(S): Brown, William; Griffin, Andrew; Walpole,

Christopher

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Ι	PATENT NO.							KIND DATE			APF	LICAT		DATE				
7	 WO	2004063193			A1 2004072			0729		WO	2004-		20040113					
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AΖ,	BA,	BE	B, BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ	Z, EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	ΙS	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG	G, MK,	MN,	MW,	MX,	MZ		
I	ΞP	1590346					A1 20051102					2004-		20040113				
I	ΞP	1590	В1	2006	1025													
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	R, IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑI	, TR,	ВG,	CZ,	EE,	HU,	SK	
Ç	JΡ	2006	5153	-		${f T}$	2006	0525		JΡ	2006-		2	0040	113			
Ā	TA	3435	71			${ m T}$	T 20061115					2004-		2	0040	113		
I	ΞS	2274	415			Т3		2007	0516		ES	2004-	7016	28		20040113		
Ţ	JS	2006	0148	850		A1		2006	0706		US	2005-	5416	64		2	0050	707
PRIOR	ΙΤΊ	Z APP	LN.	INFO	.:						SE	2003-	104			A 2	0030	116
											WO	2004-	GB61		,	W 2	0040	113

OTHER SOURCE(S): MARPAT 141:157038

GΙ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [R1 = aryl, heteroaryl, etc.; R2-5 = H, alkyl, cycloalkyl, etc.] are prepared For instance, 4-[bromo(4-carboxyphenyl)methylene]piperid ine-1-carboxylic acid tert-Bu ester (preparation given) is converted to the diethylamide (CH2Cl2, i-BuO2CCl, HNEt2), deprotected (CH2Cl2, TFA), alkylated with thiophene-2-carboxaldehyde (1,2-dichloroethane, NaHB(OAc)3), coupled to m-aminobenzeneboronic acid (PhMe/EtOH/H2O, Pd(PPh3)4, Na2CO3) and finally treated with methanesulfonic anhydride to give II. Compds. of the invention have IC50 in the range of 0.18 0.56 nM for the δ -opioid receptor. I are useful in the management of pain.
- TT 728917-19-9P, N,N-Diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1 (thien-2-ylmethyl)piperidin-4-ylidene]methyl]benzamide
 728917-20-2P 728917-21-3P 728917-22-4P,
 N,N-Diethyl-4-[[1-(2-furanylmethyl)-4-piperidinylidene][3-

RN

CN

(preparation of 4-[3-(sulfonylamino)phenyl-1-(cyclymethyl)piperidin-4-ylidenemethyl]benazmide derivs. as delta opioid receptor ligands)
728917-19-9 HCAPLUS

Benzamide, N,N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

$$\begin{array}{c|c} S & & \\ \hline \\ CH_2 & & \\ \hline \\ C-NEt_2 \\ \hline \\ O \end{array}$$

RN 728917-20-2 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 728917-19-9 CMF C29 H35 N3 O3 S2

$$\begin{array}{c|c} S & & \\ \hline \\ CH_2 & & \\ \hline \\ C-NEt_2 \\ \hline \\ O \end{array}$$

CRN 76-05-1 CMF C2 H F3 O2

RN 728917-21-3 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[1-(2-furanylmethyl)-4-piperidinylidene][3-[(methylsulfonyl)amino]phenyl]methyl]-, hydrochloride (5:6) (CA INDEX NAME)

●6/5 HCl

RN 728917-22-4 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[1-(2-furanylmethyl)-4-piperidinylidene][3-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)

RN 728917-23-5 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Ph-CH}_2 \\ & & \\$$

RN 728917-24-6 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (10:13) (CA INDEX NAME)

CM 1

CRN 728917-23-5 CMF C31 H37 N3 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 728917-25-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

RN 728917-26-8 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(3-pyridinylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

CM 1

CRN 728917-25-7 CMF C30 H36 N4 O3 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2 10533838

728917-30-4 HCAPLUS RN

Benzamide, N,N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(2-CN thiazolylmethyl)-4-piperidinylidene]methyl]- (CA INDEX NAME)

728917-31-5 HCAPLUS RN

CN Benzamide, N, N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl][1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phenyl[1-(2-methylsulfonyl)amino]phethiazolylmethyl)-4-piperidinylidene]methyl]-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

СМ 1

728917-30-4 CRN

CMF C28 H34 N4 O3 S2

CM

CRN 76-05-1 CMF C2 H F3 O2

L6 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:606441 HCAPLUS

DOCUMENT NUMBER: 141:140324

TITLE: Preparation of diarylmethylidene piperidines as

 $\delta\text{-opioid}$ receptor ligands for the treatment of

pain.

INVENTOR(S): Brown, William; Griffin, Andrew; Walpole,

Christopher

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.											LICA							
	2004063157																	
													, BW,					
													EG,					
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS	, JP	, KE	, KG,	KP,	KR,	KZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG	, MK	, MN	MW,	MX,	MZ			
ΑU	2004	12039	69		A1		2004	0729		AU	2004	-2039		20040113				
AU	2004	12039	69		В2		2007	0906										
CA	2510	400			A1		2004	0729		CA	2004	-2510	0400		2	20040	113	
EP	1587791			A1 20051026					ΕP	2004	-701		20040113					
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	R, IT	, LI	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑI	, TR	, BG	CZ,	EE,	HU,	SK		
BR	2004	10065	94		A		2005	1220		BR	2004	-659	4		2	20040	113	
CN	1735	596			А		2006	0215		CN	2004	-8000	02123		2	20040	113	
JP	2006	5153	56		${ m T}$		JΡ	2006	-5002		20040113							
													759			20040	113	
													490			20040	113	
ΙN	2005	DN02	716		A		2007	0112		IN	2005	-DN2	716		2	20050	620	
ZA	2005	0051	89		A		2006	0426		ZA	2005	-5189	9		2	20050	627	
													556			20050	707	
ИО	2005	0038	05		A		2005	1017					ō			20050	812	
RIT	Y APP	LN.	INFO	.:						SE	2003	-103			A 2	20030	116	
										-	2004	-GB1	16		W 2	20040	113	
ים פו	JIIDCE	1/91.			MADI	PAT	1/11 •	1/103	2.4									

OTHER SOURCE(S): MARPAT 141:140324

GI

$$R^2$$
 R^3
 R^3

AB Title compds. I [R1 = (un)substituted aryl, heteroaryl; R2, R3, R4, R5 = H, alkyl, cycloalkyl] and their pharmaceutically acceptable salts were prepared For example, acylation of aniline II [R6 = H], e.g., prepared from 4-(bromomethyl)benzoic acid Me ester in 8-steps, with Me chloroformate, afforded piperidine II [R6 = COOMe] as the trifluoroacetic acid salt in 38% yield. In human δ-opioid receptor binding assays, 4-examples of compds. I exhibited IC50 values ranging from 0.30-0.48 nM, e.g., the IC50 value of piperidine II [R6 = COOMe] was 0.48 nM. Compds. I are claimed useful in the management of pain.

Ι

IT 725229-70-9P 725229-71-0P 725229-72-1P 725229-73-2P 725229-74-3P 725229-75-4P 725229-76-5P 725229-78-7P 725229-79-8P 725229-80-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylmethylidene piperidines as δ -opioid receptor ligands for the treatment of pain.)

RN 725229-70-9 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 725229-71-0 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-furanylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 725229-72-1 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Ph-CH2} \\ & & \\ &$$

RN 725229-73-2 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 725229-74-3 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 725229-75-4 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 725229-70-9 CMF C30 H35 N3 O3 S

CRN 76-05-1 CMF C2 H F3 O2

RN 725229-76-5 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(2-furanylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 725229-78-7 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 725229-72-1 CMF C32 H37 N3 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

CN

RN 725229-79-8 HCAPLUS

Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][1-(4-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM :

CRN 725229-73-2 CMF C29 H34 N4 O3 S

CRN 76-05-1 CMF C2 H F3 O2

RN 725229-80-1 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]][1-(5-thiazolylmethyl)-4-piperidinylidene]methyl]phenyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 725229-74-3 CMF C29 H34 N4 O3 S

CRN 76-05-1 CMF C2 H F3 O2

IT 725229-85-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diarylmethylidene piperidines as $\delta\text{-opioid}$ receptor ligands for the treatment of pain.)

RN 725229-85-6 HCAPLUS

CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & H \\ N \\ \hline \\ C \\ \hline \\ O \\ \end{array}$$
 NH-C-OMe

L6 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:412920 HCAPLUS

DOCUMENT NUMBER: 140:423590

TITLE: Preparation of 4-(phenylpiperidin-4-

ylidenemethyl) benzamides for treatment of pain,

anxiety, or gastrointestinal disorders

INVENTOR(S): Brown, William; Griffin, Andrew

PATENT ASSIGNEE(S): Astrazeneca AB, Swed. SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	PATENT NO.						KIND DATE			APPL	ICAT	ION :		DATE				
WO	2004041784			A1	2004	0521		WO 2	003-	 SE17	 05	20031105						
	W:	ΑE,	ΑG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	GE,	
		GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,	LK,	
		LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NΙ,	NO,	NΖ,	
		OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	TM,	
		TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW			
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MΖ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	
		ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	
		TR,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML_{\prime}	MR,	ΝE,	SN,	TD,	ΤG
AU	2003	2748	85		A1		2004	0607		AU 2	003-	2748	85	20031105				
	1567496								EP 2	003-	7591	65	20031105					
EP	1567	496			В1		2007	0411										
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FΙ,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK		
JP	2006	5146												20031105				
														20031105				
	ES 2285179						2007	1116		ES 2	003-	7591	65		2	0031	105	
US	US 20060014789						2006	0119		US 2	005-	5338	38		2	0050	504	
RIORIT	ORITY APPLN. INFO.:									SE 2002-3301					A 20021107			
										WO 2	003-	SE17	05	,	W 2	0031	105	
THER SO	HER SOURCE(S):				MAR	PAT	140:	4235	90									

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted alkyl, cycloalkyl(alkyl), (hetero)aryl, R8CO, R8SO2, R8SO, R8NHCO, R8CS, or R8NHCS; ; R2 = H or (un)substituted alkyl; R3 = H or (un)substituted alkoxycarbonyl, alkyl, or cycloalkyl(alkyl); R8 = (un)substituted alkyl, (hetero)aryl(alkyl), or cycloalkyl(alkyl); or pharmaceutically acceptable salts thereof] were prepared as opioid δ receptor ligands. For example, reaction of 4-(bromomethyl)benzoic acid Me ester with P(OMe)3, followed by addition of 1-(tert-butoxycarbonyl)-4-piperidone in the presence of LDA in THF, gave

ΤТ

RN

CN

```
4-(4-methoxycarbonylbenzylidene)piperidine-1-carboxylic acid tert-Bu ester
(35%). Addition of Br2 (78%) and reaction with NaOH in MeOH provided
4-[bromo(4-carboxyphenyl)methylene]piperidine-1-carboxylic acid tert-Bu
ester (87%). Conversion to the benzoyl chloride with iso-Bu chloroformate
and amidation (73%) with Et2NH in the presence of TEA in CH2C12, followed
by coupling with 3-aminophenylboronic acid using Pd(PPh3)4 and Na2CO3 in
toluene/EtOH/H2O afforded N, N-diethyl-4-[(3-aminophenyl)(piperidin-4-
ylidene) methyl] benzamide (97%). Alkylation of the amine with benzaldehyde
and NaBH(OAc)3 in 1,2-dichloroethane gave II. In binding assays using
human 293S cells expressing cloned human opioid receptors and neomycin
resistance, most compds. of the invention exhibited activity toward the
\delta receptor with IC50 values in the range of 0.14 nM - 31.2 nM.
Exemplified compds. also showed some activity toward the \kappa and \mu
receptors with IC50 values in the ranges of 36 nM - 9680 nM and 3 nM -
5975 nM, resp. Thus, I and their pharmaceutical compns. are useful in
therapy, in particular for the treatment of gastrointestinal disorders,
anxiety, or pain (no data).
692245-00-4P 692245-02-6P 692245-04-8P
692245-06-0P 692245-09-3P 692245-13-9P
692245-17-3P 692245-21-9P 692245-25-3P
692245-29-7P 692245-33-3P 692245-37-7P
692245-53-7P 692245-57-1P 692245-61-7P
692245-65-1P 692245-69-5P 692245-73-1P
692245-77-5P 692245-81-1P 692245-86-6P
692245-90-2P 692245-94-6P 692245-98-0P
692246-02-9P 692246-06-3P 692246-10-9P
692246-14-3P 692246-18-7P 692246-22-3P
692246-26-7P 692246-34-7P 692246-38-1P
692246-46-1P 692246-50-7P 692246-54-1P
692246-58-5P 692246-62-1P 692246-66-5P
692246-78-9P 692246-82-5P 692246-87-0P
692246-91-6P 692246-95-0P 692246-99-4P
692247-03-3P 692247-07-7P 692247-11-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
   (\delta \text{ receptor agonist; preparation of (phenylpiperidinylidenemethyl)})benz
   amides as \delta receptor agonists for treatment of pain, anxiety, or
   gastrointestinal disorders)
692245-00-4 HCAPLUS
Benzamide, N,N-diethyl-4-[[3-[(phenylmethyl)amino]phenyl]-4-
piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:27) (CA INDEX NAME)
CM
     1
CRN 692244-99-8
```

CMF C30 H35 N3 O

10533838

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-02-6 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(3-furanylmethyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:21) (CA INDEX NAME)

CM 1

CRN 692245-01-5 CMF C28 H33 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-04-8 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-[(3-thienylmethyl)amino]phenyl]methyl]-, 2,2,2-trifluoroacetate (5:12) (CA INDEX NAME)

CM 1

CRN 692245-03-7 CMF C28 H33 N3 O S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-06-0 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(2-phenylethyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (2:5) (CA INDEX NAME)

CM 1

CRN 692245-05-9 CMF C31 H37 N3 O

$$\begin{array}{c|c} & & & \\ &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-09-3 HCAPLUS

CN Benzamide, 4-[[3-[[(4-chlorophenyl)methyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:23) (CAINDEX NAME)

CM 1

CRN 692245-07-1 CMF C30 H34 C1 N3 O

$$\begin{array}{c|c} & & & \\ &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-13-9 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-[[[3-(trifluoromethyl)phenyl]methyl]amino]phenyl]methyl]-, 2,2,2-trifluoroacetate (5:11) (CA INDEX NAME)

CM 1

CRN 692245-11-7 CMF C31 H34 F3 N3 O

$$\begin{array}{c|c} & & & \\ &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-17-3 HCAPLUS

CN Benzamide, 4-[[3-[[(2-chlorophenyl)methyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 692245-15-1 CMF C30 H34 C1 N3 O

$$\begin{array}{c|c} C & & H \\ \hline \\ Et_2N-C & & C1 \\ \hline \\ C & & NH-CH_2 \\ \hline \end{array}$$

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-21-9 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-[[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]methyl]-, 2,2,2-trifluoroacetate (10:21) (CA INDEX NAME)

CM 1

CRN 692245-19-5 CMF C31 H34 F3 N3 O

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

CM 2

RN 692245-25-3 HCAPLUS
CN Benzamide, N,N-diethyl-4-[[3-[(2-furanylmethyl)amino]phenyl]-4piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:23) (CA INDEX NAME)

CM 1

CRN 692245-23-1
CMF C28 H33 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-29-7 HCAPLUS
CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-[(2-thienylmethyl)amino]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 692245-27-5 CMF C28 H33 N3 O S

CRN 76-05-1 CMF C2 H F3 O2

$$F - \begin{matrix} F \\ | \\ C - CO_2H \\ | \\ F \end{matrix}$$

RN 692245-33-3 HCAPLUS

CN Benzamide, 4-[[3-[(cyclohexylmethyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:23) (CA INDEX NAME)

CM 1

CRN 692245-31-1 CMF C30 H41 N3 O

$$\begin{array}{c|c} & & & \\ &$$

CM 2

RN 692245-37-7 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-(propylamino)phenyl]methyl]-, 2,2,2-trifluoroacetate (10:29) (CA INDEX NAME)

CM 1

CRN 692245-35-5 CMF C26 H35 N3 O

$$\begin{array}{c|c} C & H \\ N \\ C \\ NHPr-n \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-53-7 HCAPLUS

CN Benzamide, 4-[[3-(cyclopentylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:14) (CA INDEX NAME)

CM 1

CRN 692245-51-5 CMF C29 H39 N3 O

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-57-1 HCAPLUS

CN Benzamide, 4-[[3-(benzoylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 692245-55-9 CMF C30 H33 N3 O2

CM 2

RN 692245-61-7 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (5:9) (CA INDEX NAME)

CM 1

CRN 692245-59-3 CMF C31 H35 N3 O2

$$\begin{array}{c|c} & & & \\ & & \\ & & \\ \text{Ph-CH}_2-\text{C-NH} & & \\ & & \\ & & \\ & & \\ \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-65-1 HCAPLUS

CN Benzamide, 4-[[3-[(cyclohexylcarbonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 692245-63-9 CMF C30 H39 N3 O2

$$\begin{array}{c|c} & & & \\ & & \\ & & \\ Et_2N-C & & \\$$

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-69-5 HCAPLUS

CN Benzamide, 4-[[3-[(2-cyclohexylacetyl)amino]phenyl]-4piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (2:3) (CA
INDEX NAME)

CM 1

CRN 692245-67-3 CMF C31 H41 N3 O2

$$\begin{array}{c|c} & & & \\ &$$

CM 2

RN 692245-73-1 HCAPLUS

CN Benzeneacetamide, 2-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 692245-71-9 CMF C31 H34 C1 N3 O2

$$\begin{array}{c|c} C & H \\ N & \\ Et_2N-C & \\ C & NH-C-CH_2 \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-77-5 HCAPLUS

CN Benzeneacetamide, 3-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 692245-75-3 CMF C31 H34 C1 N3 O2

$$\begin{array}{c|c} C & H \\ N & \\ C & \\ C$$

10533838

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-81-1 HCAPLUS

CN 2-Thiopheneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-5-methyl-, 2,2,2-trifluoroacetate (5:6) (CA INDEX NAME)

CM 1

CRN 692245-79-7 CMF C30 H35 N3 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-86-6 HCAPLUS

CN 2-Thiopheneacetamide, 5-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CRN 692245-84-4 CMF C29 H32 C1 N3 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-90-2 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -methyl-, (α S)-, 2,2-trifluoroacetate (5:8) (CA INDEX NAME)

CM 1

CRN 692245-88-8 CMF C32 H37 N3 O2

Absolute stereochemistry.

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-94-6 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -methyl-, (α R)-, 2,2,2-trifluoroacetate (10:17) (CA INDEX NAME)

CM 1

CRN 692245-92-4 CMF C32 H37 N3 O2

Absolute stereochemistry.

CRN 76-05-1 CMF C2 H F3 O2

RN 692245-98-0 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -ethyl-, (α S)-, 2,2-trifluoroacetate (5:18) (CA INDEX NAME)

CM 1

CRN 692245-96-8 CMF C33 H39 N3 O2

Absolute stereochemistry.

CM 2

RN 692246-02-9 HCAPLUS
CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4piperidinylidenemethyl]phenyl]-α-ethyl-, (αR)-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 692246-00-7
CMF C33 H39 N3 O2

Absolute stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-06-3 HCAPLUS

CN Benzamide, 4-[[3-(benzoylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:13) (CA INDEX NAME)

CM 1

CRN 692246-04-1 CMF C31 H35 N3 O2

$$\begin{array}{c|c} H \\ N \\ \hline \\ N - C - Ph \\ Me O \end{array}$$

CRN 76-05-1 CMF C2 H F3 O2

$${\scriptstyle F-C-CO_2H\atop \mid\atop F}$$

RN 692246-10-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[[(phenylamino)carbonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 692246-08-5 CMF C30 H34 N4 O2

CM 2

RN 692246-14-3 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:7) (CA INDEX NAME)

CM 1

CRN 692246-12-1 CMF C31 H36 N4 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-18-7 HCAPLUS

CN 1-Piperidinecarboxamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (5:9) (CA INDEX NAME)

CM 1

CRN 692246-16-5 CMF C29 H38 N4 O2

$$\begin{array}{c|c} C & H \\ N \\ C & NH \\ C & NH \end{array}$$

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-22-3 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(phenylsulfonyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (1:4) (CA INDEX NAME)

CM 1

CRN 692246-20-1 CMF C29 H33 N3 O3 S

$$\begin{array}{c|c} C & H \\ N \\ C & \\ NH-S-Ph \\ O \\ O \\ \end{array}$$

CM 2

RN 692246-26-7 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[[(phenylmethyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:14) (CA INDEX NAME)

CM 1

CRN 692246-24-5 CMF C30 H35 N3 O3 S

$$\begin{array}{c|c} \mathbf{C} & \mathbf{H} & \mathbf{H} \\ \mathbf{Et}_{2}\mathbf{N} - \mathbf{C} & \mathbf{O} \\ \mathbf{C} & \mathbf{NH} - \mathbf{S} - \mathbf{CH}_{2} - \mathbf{Ph} \\ \mathbf{O} & \mathbf{O} \\ \mathbf{O} & \mathbf{O} \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-34-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-(methylphenylamino)phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:13) (CA INDEX NAME)

CM 1

CRN 692246-32-5 CMF C30 H35 N3 O

$$\begin{array}{c|c} H \\ N \\ C \\ N-Me \\ O \\ \end{array}$$

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-38-1 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-(ethylphenylamino)phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 692246-36-9 CMF C31 H37 N3 O

$$\begin{array}{c|c} H \\ N \\ C \\ \hline \\ C \\ \hline \\ N-Et \\ \hline \\ Ph \\ C \\ \hline \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-46-1 HCAPLUS

Benzamide, N,N-diethyl-4-[[3-[[(1S)-1-phenylethyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:11) (CA INDEX NAME)

CM 1

CRN 692246-44-9 CMF C31 H37 N3 O

Absolute stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-50-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[[(1R)-1-phenylethyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:37) (CA INDEX NAME)

CM :

CRN 692246-48-3 CMF C31 H37 N3 O

Absolute stereochemistry.

$$\begin{array}{c|c} H \\ N \\ \hline \\ Et_2N \\ \hline \\ O \\ \end{array}$$

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-54-1 HCAPLUS

CN Benzamide, 4-[[3-[[(1R)-1-cyclohexylethyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:11) (CA INDEX NAME)

CM 1

CRN 692246-52-9 CMF C31 H43 N3 O

Absolute stereochemistry.

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-58-5 HCAPLUS

CN Benzamide, 4-[[3-[[(1S)-1-cyclohexylethyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (10:19) (CA INDEX NAME)

CM 1

CRN 692246-56-3 CMF C31 H43 N3 O

Absolute stereochemistry.

CM 2

RN 692246-62-1 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(1-methyl-1-phenylethyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:29) (CA INDEX NAME)

CM 1

CRN 692246-60-9 CMF C32 H39 N3 O

$$\begin{array}{c|c} & & & H \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-66-5 HCAPLUS

CN Benzamide, 4-[[3-(cyclohexylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (5:18) (CA INDEX NAME)

CM 1

CRN 692246-64-3 CMF C30 H41 N3 O

$$\begin{array}{c|c} C & H \\ N \\ \\ Et_2N-C \\ \hline \\ C & N \\ \end{array}$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-78-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(2-ethyl-1-oxobutyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:9) (CA INDEX NAME)

CM 1

CRN 692246-76-7 CMF C29 H39 N3 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-82-5 HCAPLUS

CN 1H-Benzotriazole-5-carboxamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-1-methyl-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692246-80-3 CMF C31 H34 N6 O2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-87-0 HCAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692246-85-8 CMF C29 H31 C1 N4 O2

$$\begin{array}{c|c} C & NH-C & N\\ NH-$$

CM 2

RN 692246-91-6 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(2-methoxybenzoyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692246-89-2 CMF C31 H35 N3 O3

$$\begin{array}{c|c} & & & \\ &$$

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692246-95-0 HCAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692246-93-8 CMF C32 H33 N5 O2

CRN 76-05-1 CMF C2 H F3 O2

$${\tiny \begin{array}{c}F\\F-C-CO_2H\\|\\F\end{array}}$$

RN 692246-99-4 HCAPLUS

CN Benzamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-2,5-difluoro-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692246-97-2 CMF C30 H31 F2 N3 O2

$$\begin{array}{c|c} & & & \\ &$$

CM 2

RN 692247-03-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692247-01-1 CMF C28 H30 C1 N3 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 692247-07-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(3-methylbenzoyl)amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (10:11) (CA INDEX NAME)

CM 1

CRN 692247-05-5 CMF C31 H35 N3 O2

$$\mathsf{Et}_2\mathsf{N}-\mathsf{C} \\ \mathsf{C} \\ \mathsf{NH}-\mathsf{C} \\ \mathsf{Me}$$

CRN 76-05-1 CMF C2 H F3 O2

RN 692247-11-3 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[[(methylphenylamino)carbonyl]amino]phenyl]-4-piperidinylidenemethyl]-, 2,2,2-trifluoroacetate (5:9) (CA INDEX NAME)

CM 1

CRN 692247-09-9 CMF C31 H36 N4 O2

$$\begin{array}{c|c} Ph & O \\ & | & | \\ Me-N-C-NH \\ \end{array}$$

CM 2

```
ΤТ
    692244-99-8P, 4-[[3-(Benzylamino)phenyl](piperidin-4-
    ylidene) methyl]-N, N-diethylbenzamide 692245-01-5P,
    N, N-Diethyl-4-[[3-[(3-furylmethyl)amino]phenyl](piperidin-4-
    ylidene)methyl]benzamide 692245-03-7P, N,N-Diethyl-4-[(piperidin-
    4-ylidene)[3-[[(thien-3-yl)methyl]amino]phenyl]methyl]benzamide
    692245-05-9P, N,N-Diethyl-4-[[3-[(2-phenylethyl)amino]phenyl](pipe
    ridin-4-vlidene) methyl]benzamide 692245-07-1P,
    4-[[3-[(4-Chlorobenzyl)amino]phenyl](piperidin-4-ylidene)methyl]-N,N-
    diethylbenzamide 692245-11-7P, N,N-Diethyl-4-[(piperidin-4-
    ylidene) [3-[[3-(trifluoromethyl)benzyl]amino]phenyl]methyl]benzamide
    692245-15-1P, 4-[[3-[(2-Chlorobenzyl)amino]phenyl](piperidin-4-
    ylidene) methyl]-N, N-diethylbenzamide 692245-19-5P,
    N, N-Diethyl-4-[(piperidin-4-ylidene)[3-[[4-(trifluoromethyl)benzyl]amino]p
    henyl]methyl]benzamide 692245-23-1P, N,N-Diethyl-4-[[3-[(2-
    furylmethyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
    692245-27-5P, N,N-Diethyl-4-[(piperidin-4-ylidene)[3-[[(thien-2-
    yl)methyl]amino]phenyl]methyl]benzamide 692245-31-1P,
    4-[[3-[(Cyclohexylmethyl)amino]phenyl](piperidin-4-ylidene)methyl]-N, N-
    diethylbenzamide 692245-35-5P, N,N-Diethyl-4-[(piperidin-4-
    ylidene) [3-(propylamino)phenyl]methyl]benzamide 692245-51-5P,
    4-[[3-[Cyclopentyl(methyl)amino]phenyl](piperidin-4-ylidene)methyl]-N, N-
    diethylbenzamide 692245-55-9P, 4-[[3-
     (Benzoylamino)phenyl](piperidin-4-ylidene)methyl]-N, N-diethylbenzamide
    692245-59-3P, N,N-Diethyl-4-[[3-[(phenylacetyl)amino]phenyl](piper
    idin-4-ylidene) methyl] benzamide 692245-63-9P,
    4-[[3-[(Cyclohexylcarbonyl)amino]phenyl](piperidin-4-ylidene)methyl]-N,N-
    diethylbenzamide 692245-67-3P, 4-[[3-
    [(Cyclohexylacetyl)amino]phenyl](piperidin-4-ylidene)methyl]-N,N-
    diethylbenzamide 692245-71-9P, 4-[[3-[[(2-
    Chlorophenyl) acetyl] amino] phenyl] (piperidin-4-ylidene) methyl] -N, N-
    diethylbenzamide 692245-75-3P, 4-[[3-[[(3-
    Chlorophenyl)acetyl]amino]phenyl](piperidin-4-ylidene)methyl]-N,N-
    diethylbenzamide 692245-79-7P, N,N-Diethyl-4-[[3-[[(5-
    methylthien-2-yl)acetyl]amino]phenyl](piperidin-4-ylidene)methyl]benzamide
    692245-84-4P, 4-[[3-[[(5-Chlorothien-2-
    yl)acetyl]amino]phenyl](piperidin-4-ylidene)methyl]-N, N-diethylbenzamide
    692245-88-8P, (S)-N,N-Diethyl-4-[[3-[(2-
    phenylpropanoyl)amino|phenyl|(piperidin-4-ylidene)methyl|benzamide
    692245-92-4P, (R)-N,N-Diethyl-4-[[3-[(2-
    phenylpropanoyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
    692245-96-8P, (S)-N, N-Diethyl-4-[[3-[(2-
    phenylbutanoyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
    692246-00-7P, (R)-N, N-Diethyl-4-[[3-[(2-
    phenylbutanoyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
    692246-04-1P, 4-[[3-[Benzoyl(methyl)amino]phenyl](piperidin-4-
    ylidene) methyl]-N, N-diethylbenzamide 692246-08-5P,
    4-[[3-[(Anilinocarbonyl)amino]phenyl](piperidin-4-ylidene)methyl]-N,N-
    diethylbenzamide 692246-12-1P, 4-[[3-
    [[(Benzylamino)carbonyl]amino]phenyl](piperidin-4-ylidene)methyl]-N, N-
    diethylbenzamide 692246-16-5P, N-[3-[[4-
    [(Diethylamino)carbonyl]phenyl](piperidin-4-ylidene)methyl]phenyl]piperidi
    ne-1-carboxamide 692246-20-1P, N,N-Diethyl-4-[[3-
     [(phenylsulfonyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
    692246-24-5P, 4-[[3-[(Benzylsulfonyl)amino]phenyl](piperidin-4-
    ylidene) methyl]-N, N-diethylbenzamide 692246-32-5P,
    N, N-Diethyl-4-[[3-[methyl(phenyl)amino]phenyl](piperidin-4-
```

```
ylidene)methyl]benzamide 692246-36-9P, N,N-Diethyl-4-[[3-
[ethyl(phenyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
692246-44-9P, (S)-N, N-Diethyl-4-[[3-[(1-
phenylethyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
692246-48-3P, (R)-N,N-Diethyl-4-[[3-[(1-
phenylethyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
692246-52-9P, (R)-4-[[3-[(1-Cyclohexylethyl)amino]phenyl](piperidi
n-4-ylidene) methyl]-N, N-diethylbenzamide 692246-56-3P,
(S)-4-[[3-[(1-Cyclohexylethyl)amino]phenyl](piperidin-4-ylidene)methyl]-
N, N-diethylbenzamide 692246-60-9P, N, N-Diethyl-4-[[3-[(1-methyl-4-[3-[(1-methyl-4-[3-[(1-methyl-4-[3-[3-[4])])]])]])
1-phenylethyl)amino]phenyl](piperidin-4-ylidene)methyl]benzamide
692246-64-3P, 4-[[3-[Cyclohexyl(methyl)amino]phenyl](piperidin-4-
ylidene) methyl]-N, N-diethylbenzamide 692246-76-7P,
N, N-Diethyl-4-[[3-[(2-ethyl-1-oxobutyl)amino]phenyl]-4-
piperidinylidenemethyl]benzamide 692246-80-3P
692246-85-8P, 6-Chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]phenyl]-4-[4-[(diethylamino)carbonyl]-4-[4-[(diethylamino)carbonyl]-4-[4-[(diethylamino)carbonyl]-4-[4-[(diethylamino)carbonyl
piperidinylidenemethyl]phenyl]-3-pyridinecarboxamide 692246-89-2P
, N-[3-[[4-[(Diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl
]-2-methoxybenzamide 692246-93-8P, N-[3-[[4-
[(Diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-2-
quinoxalinecarboxamide 692246-97-2P,
N-[3-[[4-[(Diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-
2,5-difluorobenzamide 692247-01-1P, 3-Chloro-N-[3-[[4-
[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-2-
thiophenecarboxamide 692247-05-5P, N-[3-[[4-
[(Diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-3-
methylbenzamide 692247-09-9P, N,N-Diethyl-4-[[3-
[[[methyl(phenyl)amino]carbonyl]amino]phenyl]-4-
piperidinylidenemethyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
      (δ receptor agonist; preparation of (phenylpiperidinylidenemethyl)benz
      amides as \delta receptor agonists for treatment of pain, anxiety, or
      gastrointestinal disorders)
692244-99-8 HCAPLUS
Benzamide, N, N-diethyl-4-[[3-[(phenylmethyl)amino]phenyl]-4-
piperidinvlidenemethyl]- (CA INDEX NAME)
```

$$\begin{array}{c} H \\ N \\ O \\ C - NEt_2 \end{array}$$
 Ph- CH₂- NH

```
RN 692245-01-5 HCAPLUS
CN Benzamide, N,N-diethyl-4-[[3-[(3-furanylmethyl)amino]phenyl]-4-
piperidinylidenemethyl]- (CA INDEX NAME)
```

RN

CN

RN 692245-03-7 HCAPLUS

CN Benzamide, N, N-diethyl-4-[4-piperidinylidene[3-[(3-thienylmethyl)amino]phenyl]methyl]- (CA INDEX NAME)

RN 692245-05-9 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(2-phenylethyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} \mathbf{Et_2N-C} & \mathbf{H} \\ \mathbf{N} \\ \mathbf{C} \\ \mathbf{NH-CH_2-CH_2-Ph} \end{array}$$

RN 692245-07-1 HCAPLUS

CN Benzamide, 4-[[3-[[(4-chlorophenyl)methyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ \text{Et}_2\text{N} - \text{C} & & \\$$

RN 692245-11-7 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-[[[3-(trifluoromethyl)phenyl]methyl]amino]phenyl]methyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ &$$

RN 692245-15-1 HCAPLUS

CN Benzamide, 4-[[3-[[(2-chlorophenyl)methyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 692245-19-5 HCAPLUS

CN Benzamide, N, N-diethyl-4-[4-piperidinylidene[3-[[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]methyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & H & H & \\ C & H & N & \\ C & H & N & \\ C & NH & CH_2 & \\ \end{array}$$

10533838

RN 692245-23-1 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(2-furanylmethyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 692245-27-5 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-[(2-thienylmethyl)amino]phenyl]methyl]- (CA INDEX NAME)

RN 692245-31-1 HCAPLUS

CN Benzamide, 4-[[3-[(cyclohexylmethyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ N \\ C & NH-CH_2 \end{array}$$

RN 692245-35-5 HCAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinylidene[3-(propylamino)phenyl]methyl]- (CA INDEX NAME)

$$\mathsf{Et}_2\mathsf{N}-\mathsf{C} \\ \\ \mathsf{NHPr-n} \\ \\ \mathsf{NHPr-$$

RN 692245-51-5 HCAPLUS

CN Benzamide, 4-[[3-(cyclopentylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 692245-55-9 HCAPLUS

CN Benzamide, 4-[[3-(benzoylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & H \\ N \\ \hline \\ C \\ \hline \\ NH-C-Ph \\ \\ \\ O \\ \end{array}$$

RN 692245-59-3 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ & & \\ \text{Ph-CH}_2-\text{C-NH} & & \\ & & \\ & & \\ & & \\ \end{array}$$

RN 692245-63-9 HCAPLUS

CN Benzamide, 4-[[3-[(cyclohexylcarbonyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ H \\ N \\ C & NH - C \\ \end{array}$$

RN 692245-67-3 HCAPLUS

CN Benzamide, 4-[[3-[(2-cyclohexylacetyl)amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ N \\ C & \\ NH - C - CH_2 \\ \end{array}$$

RN 692245-71-9 HCAPLUS

CN Benzeneacetamide, 2-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 692245-75-3 HCAPLUS

CN Benzeneacetamide, 3-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ \text{Et}_2\text{N} - \text{C} & & \\$$

RN 692245-79-7 HCAPLUS

CN 2-Thiopheneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-5-methyl- (CA INDEX NAME)

RN 692245-84-4 HCAPLUS

CN 2-Thiopheneacetamide, 5-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

RN 692245-88-8 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -methyl-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 692245-92-4 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -methyl-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 692245-96-8 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -ethyl-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 692246-00-7 HCAPLUS

CN Benzeneacetamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- α -ethyl-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 692246-04-1 HCAPLUS

CN Benzamide, 4-[[3-(benzoylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

$$\begin{array}{c|c} & H \\ N \\ \hline \\ C \\ \hline \\ N-C-Ph \\ \hline \\ Me & O \\ \end{array}$$

10533838

RN 692246-08-5 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[[(phenylamino)carbonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 692246-12-1 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 692246-16-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ H \\ H \\ C & NH-C-N \end{array}$$

RN 692246-20-1 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(phenylsulfonyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ H \\ N \\ C & \\ NH-S-Ph \\ O \\ \end{array}$$

RN 692246-24-5 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[[(phenylmethyl)sulfonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ N \\ C & O \\ NH - S - CH_2 - Ph \\ O \\ O \end{array}$$

RN 692246-32-5 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-(methylphenylamino)phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\mathsf{Et}_2\mathsf{N} - \mathsf{C} \\ \mathsf{O} \\ \mathsf{Ph} \\ \mathsf{D} \\ \mathsf{Ph} \\ \mathsf{D} \\ \mathsf{Ph} \\ \mathsf{D} \\ \mathsf{D} \\ \mathsf{Ph} \\ \mathsf{D} \\ \mathsf{D$$

RN 692246-36-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-(ethylphenylamino)phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} H \\ N \\ C \\ \\ C \\ \\ N-Et \\ \\ Ph \\ \\ O \end{array}$$

RN 692246-44-9 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[[(1S)-1-phenylethyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c} H \\ N \\ \end{array}$$

RN 692246-48-3 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[[(1R)-1-phenylethyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} H \\ N \\ \end{array}$$

RN 692246-52-9 HCAPLUS

CN Benzamide, 4-[[3-[[(1R)-1-cyclohexylethyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 692246-56-3 HCAPLUS

CN Benzamide, 4-[[3-[[(1S)-1-cyclohexylethyl]amino]phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 692246-60-9 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(1-methyl-1-phenylethyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & H \\ & & \\ &$$

RN 692246-64-3 HCAPLUS

CN Benzamide, 4-[[3-(cyclohexylmethylamino)phenyl]-4-piperidinylidenemethyl]-N,N-diethyl- (CA INDEX NAME)

RN 692246-76-7 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(2-ethyl-1-oxobutyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

RN 692246-80-3 HCAPLUS

CN 1H-Benzotriazole-5-carboxamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-1-methyl- (CA INDEX NAME)

$$\begin{array}{c|c} C & NH-C & NH-$$

10533838

RN 692246-85-8 HCAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & NH-C & N\\ \hline N\\ N\\ N\\ H & \\ \end{array}$$

RN 692246-89-2 HCAPLUS

CN Benzamide, N, N-diethyl-4-[[3-[(2-methoxybenzoyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ N \\ C & NH \\ C & MeO \end{array}$$

RN 692246-93-8 HCAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

RN 692246-97-2 HCAPLUS

CN Benzamide, N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]-2,5-difluoro- (CA INDEX NAME)

10533838

$$\begin{array}{c|c} C & H \\ H \\ N \\ C & NH-C \\ \end{array}$$

RN 692247-01-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[[4-[(diethylamino)carbonyl]phenyl]-4-piperidinylidenemethyl]phenyl]- (CA INDEX NAME)

RN 692247-05-5 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[(3-methylbenzoyl)amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & H \\ H \\ N \\ C & NH \\ \end{array}$$

RN 692247-09-9 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[3-[[(methylphenylamino)carbonyl]amino]phenyl]-4-piperidinylidenemethyl]- (CA INDEX NAME)

=> file caold COST IN U.S. DOLLARS SINCE FILE TOTAL. ENTRY SESSION FULL ESTIMATED COST 43.53 230.47 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -5.60-5.60

FILE 'CAOLD' ENTERED AT 17:34:18 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 17:28:11 ON 26 JUN 2008)

FILE 'REGISTRY' ENTERED AT 17:28:41 ON 26 JUN 2008
L1 STRUCTURE UPLOADED
L2 17 S L1
L3 277 S L1 FULL
L4 0 S L3 AND BROWN, W?/AU

FILE 'HCAPLUS' ENTERED AT 17:33:17 ON 26 JUN 2008
7 S L3

L5 7 S L3 L6 7 S L5 AND BROWN, W?/AU FILE 'CAOLD' ENTERED AT 17:34:18 ON 26 JUN 2008

=> s 13

L7 0 L3

=> file medline

SINCE FILE TOTAL ENTRY SESSION COST IN U.S. DOLLARS FULL ESTIMATED COST 230.93

0.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY

CA SUBSCRIBER PRICE 0.00 -5.60

FILE 'MEDLINE' ENTERED AT 17:34:59 ON 26 JUN 2008

FILE LAST UPDATED: 25 Jun 2008 (20080625/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

=> s 13

L8 0 L3

=> s pain and piperidine and benzamide

311884 PAIN

5195 PAINS

314848 PAIN

(PAIN OR PAINS)

4653 PIPERIDINE

21786 PIPERIDINES

24371 PIPERIDINE

(PIPERIDINE OR PIPERIDINES)

2560 BENZAMIDE

6648 BENZAMIDES

7730 BENZAMIDE

(BENZAMIDE OR BENZAMIDES)

1.9 28 PAIN AND PIPERIDINE AND BENZAMIDE

=> s 19 and review/dt

1362532 REVIEW/DT

2 L9 AND REVIEW/DT $T_{1}10$

 \Rightarrow d 110, ibib abs hitstr, 1-2

'HITSTR' IS NOT A VALID FORMAT FOR FILE 'MEDLINE'

The following are valid formats:

The default display format is BIB.

ABS ---- AB

ALL ---- AN, DN, TI, AU, CS, NC, SO, CM, CY, DT, LA, FS, NCT, OS,

EM, ED, AB, ST, CT, NA, RN, CN, GEN

BIB ---- AN, DN, TI, AU, CS, NC, SO, CY, DT, LA, FS, NCT, OS, EM, ED CBIB --- AN, DN, TI, AU, CS, NC, SO, CY, DT, LA, FS, NCT, OS, EM, ED

DALL --- ALL, delimited for post processing

IABS --- ABS, with a text label

IALL --- ALL, indented with text labels IBIB --- BIB, indented with text labels

IND ---- ST, CT, NA, RN, CN, GEN

TRIAL -- TI, ST, CT, NA, RN, CN, GEN

(SAM, TRI, FREE)

HIT ---- All fields containing hit terms

HITIND - IND

KWIC --- All hit terms plus 20 words on either side OCC ---- List of display fields containing hit terms

Hit terms will be highlighted in all available fields except CM and PY.

To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'BIB'; 'AB'; 'SO,ST'. You may specify the format fields in any order, and the information will be displayed in the same order as the format specification.

The same formats (except for HIT, HITIND, KWIC, and OCC) may be used with the DISPLAY ACC command to display the record for a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d 110, ibib abs, 1-2

L10 ANSWER 1 OF 2 MEDLINE on STN ACCESSION NUMBER: 94023158 MEDLINE DOCUMENT NUMBER: PubMed ID: 8210494

TITLE: SR 48968, a neurokinin A (NK2) receptor antagonist.

AUTHOR: Emonds-Alt X; Advenier C; Croci T; Manara L; Neliat G;

Poncelet M; Proietto V; Santucci V; Soubrie P; Van Broeck

D; +

CORPORATE SOURCE: Sanofi Recherche, Montpellier, France.

SOURCE: Regulatory peptides, (1993 Jul 2) Vol. 46, No. 1-2, pp.

31-6. Ref: 16

Journal code: 8100479. ISSN: 0167-0115.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199310

ENTRY DATE: Entered STN: 17 Jan 1994

Last Updated on STN: 6 Feb 1998 Entered Medline: 28 Oct 1993

L10 ANSWER 2 OF 2 MEDLINE on STN ACCESSION NUMBER: 93092843 MEDLINE

DOCUMENT NUMBER: PubMed ID: 1281070

TITLE: Diabetic gastroparesis. A critical reappraisal of new

treatment strategies.

AUTHOR: Drenth J P; Engels L G

CORPORATE SOURCE: Department of Medicine, University Hospital, Radboud,

Nijmegen, The Netherlands.

SOURCE: Drugs, (1992 Oct) Vol. 44, No. 4, pp. 537-53. Ref: 126

Journal code: 7600076. ISSN: 0012-6667.

PUB. COUNTRY: New Zealand DOCUMENT TYPE: (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE II)

Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199301

ENTRY DATE: Entered STN: 29 Jan 1993

Last Updated on STN: 29 Jan 1999

Entered Medline: 8 Jan 1993

AΒ Delayed gastric emptying, gastroparesis, is one of the sequelae of diabetes mellitus. Symptoms may include postprandial nausea, epigastric pain, bloating, vomiting, early satiety and unpredictable blood sugar fluctuations. Nowadays diagnosis is made by the measurement of gastric emptying with a radionuclide test meal. Using this technique some 50% of diabetic patients show signs of disordered gastric emptying. Relief is best delivered by agents promoting gastric emptying. In phase II single-dose studies metoclopramide, domperidone, cisapride, erythromycin and renzapride were all able to enhance gastric evacuation of solid and liquid meals in patients with diabetic gastroparesis. A few short term studies support the efficacy of domperidone and renzapride, but long term trials are lacking. Erythromycin, mimicking the potent gastrokinetic effect of motilin, may hold considerable promise for the future. Experience with erythromycin in diabetic gastroparesis is nonetheless very limited. To some extent the therapeutic effectiveness of metoclopramide and cisapride has been established in placebo-controlled trials. In trials with a placebo-controlled crossover design, however, only metoclopramide showed a sustained positive effect. Metoclopramide, which combines gastrokinetic and antiemetic properties seems, so far, the best therapeutic option in diabetic gastroparesis. Cisapride may be considered as a good alternative in cases where limited efficacy or side effects preclude the use of metoclopramide.

=> s gastrointestinal () disorder? and piperid? and benzamide

191748 GASTROINTESTINAL

3 GASTROINTESTINALS

191751 GASTROINTESTINAL

(GASTROINTESTINAL OR GASTROINTESTINALS)

1002581 DISORDER?

2787 GASTROINTESTINAL (W) DISORDER?

27719 PIPERID?

2560 BENZAMIDE

6648 BENZAMIDES

7730 BENZAMIDE

(BENZAMIDE OR BENZAMIDES)

L11 5 GASTROINTESTINAL (W) DISORDER? AND PIPERID? AND BENZAMIDE

=> s l11 and review/dt 1362532 REVIEW/DT

L12 1 L11 AND REVIEW/DT

=> d 112, ibib abs, 1

L12 ANSWER 1 OF 1 MEDLINE on STN ACCESSION NUMBER: 96134443 MEDLINE DOCUMENT NUMBER: PubMed ID: 8527013

TITLE: A risk-benefit assessment of cisapride in the treatment of

gastrointestinal disorders.

AUTHOR: Tack J; Coremans G; Janssens J

CORPORATE SOURCE: Department of Internal Medicine, University Hospital

Gasthuisberg, University of Leuven, Belgium.

SOURCE: Drug safety: an international journal of medical

toxicology and drug experience, (1995 Jun) Vol. 12, No. 6,

pp. 384-92. Ref: 103

Journal code: 9002928. ISSN: 0114-5916.

PUB. COUNTRY: New Zealand

DOCUMENT TYPE: (COMPARATIVE STUDY)

Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199601

ENTRY DATE: Entered STN: 20 Feb 1996

Last Updated on STN: 29 Jan 1999 Entered Medline: 29 Jan 1996

AΒ Cisapride is a substituted benzamide compound that stimulates motor activity in all segments of the gastrointestinal tract by enhancing the release of acetylcholine from the enteric nervous system. Cisapride is administered orally in the treatment of gastro-oesophageal reflux disease, functional dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction syndromes and chronic constipation. In gastro-oesophageal reflux disease in both adults and children, cisapride provides symptomatic improvement and mucosal healing. Long term treatment with cisapride is effective in the prevention of relapse of oesophagitis. Cisapride improves gastric emptying rates and improves symptoms in patients with gastroparesis of various origins. Unlike domperidone and metoclopramide, long term administration of cisapride seems to result in persistently enhanced gastric emptying. Cisapride is also effective in improving symptoms in patients with functional dyspepsia. In comparative studies in patients with functional dyspepsia, cisapride was at least as effective as metoclopramide, domperidone, clebopride, ranitidine and cimetidine. Cisapride increases stool frequency and reduces laxative consumption in patients with idiopathic constipation. Severe cases of slow transit constipation seem refractory to cisapride. Clinical studies also indicate that cisapride might be effective in the treatment of chronic intestinal pseudo-obstruction, postoperative ileus, peptic ulcer and irritable bowel syndrome. Further clinical studies are warranted to define the role of cisapride in these conditions. The dosage of cisapride ranges from 5mg 3 times daily to 20mg twice daily. Cisapride is generally well tolerated, both during short and long term treatment. In children, cisapride is also well tolerated in doses of 0.2 to 0.3 mg/kg, 3 to 4 times daily.(ABSTRACT TRUNCATED AT 250 WORDS)

```
=> s anxiety and piperid? and benzamide
         96773 ANXIETY
         1228 ANXIETIES
         97531 ANXIETY
                (ANXIETY OR ANXIETIES)
         27719 PIPERID?
          2560 BENZAMIDE
          6648 BENZAMIDES
          7730 BENZAMIDE
                (BENZAMIDE OR BENZAMIDES)
L13
            14 ANXIETY AND PIPERID? AND BENZAMIDE
=> s 113 and review/dt
      1362532 REVIEW/DT
L14
           0 L13 AND REVIEW/DT
=> s biosis
L15
        395 BIOSIS
=> d his
     (FILE 'HOME' ENTERED AT 17:28:11 ON 26 JUN 2008)
     FILE 'REGISTRY' ENTERED AT 17:28:41 ON 26 JUN 2008
L1
              STRUCTURE UPLOADED
            17 S L1
L2
L3
           277 S L1 FULL
             0 S L3 AND BROWN, W?/AU
L4
     FILE 'HCAPLUS' ENTERED AT 17:33:17 ON 26 JUN 2008
L5
             7 S L3
              7 S L5 AND BROWN, W?/AU
L6
    FILE 'CAOLD' ENTERED AT 17:34:18 ON 26 JUN 2008
L7
             0 S L3
     FILE 'MEDLINE' ENTERED AT 17:34:59 ON 26 JUN 2008
L8
             0 S L3
L9
             28 S PAIN AND PIPERIDINE AND BENZAMIDE
L10
             2 S L9 AND REVIEW/DT
L11
             5 S GASTROINTESTINAL () DISORDER? AND PIPERID? AND BENZAMIDE
L12
             1 S L11 AND REVIEW/DT
L13
            14 S ANXIETY AND PIPERID? AND BENZAMIDE
L14
             0 S L13 AND REVIEW/DT
L15
           395 S BIOSIS
=> s 13
           0 L3
L16
=> file biosis
COST IN U.S. DOLLARS
                                                 SINCE FILE
                                                               TOTAL
                                                             SESSION
                                                     ENTRY
FULL ESTIMATED COST
                                                      13.64
                                                              244.57
```

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY
SESSION CA SUBSCRIBER PRICE 0.00 -5.60 FILE 'BIOSIS' ENTERED AT 17:38:10 ON 26 JUN 2008 Copyright (c) 2008 The Thomson Corporation FILE COVERS 1926 TO DATE. CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE. RECORDS LAST ADDED: 25 June 2008 (20080625/ED) BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing. => d his (FILE 'HOME' ENTERED AT 17:28:11 ON 26 JUN 2008) FILE 'REGISTRY' ENTERED AT 17:28:41 ON 26 JUN 2008 L1STRUCTURE UPLOADED 17 S L1 L2L3 277 S L1 FULL L40 S L3 AND BROWN, W?/AU FILE 'HCAPLUS' ENTERED AT 17:33:17 ON 26 JUN 2008 L57 S L3 7 S L5 AND BROWN, W?/AU L6 FILE 'CAOLD' ENTERED AT 17:34:18 ON 26 JUN 2008 L7 0 S L3 FILE 'MEDLINE' ENTERED AT 17:34:59 ON 26 JUN 2008 L8 0 S L3 28 S PAIN AND PIPERIDINE AND BENZAMIDE L9 L10 2 S L9 AND REVIEW/DT L11 5 S GASTROINTESTINAL () DISORDER? AND PIPERID? AND BENZAMIDE L12 1 S L11 AND REVIEW/DT L13 14 S ANXIETY AND PIPERID? AND BENZAMIDE L14 0 S L13 AND REVIEW/DT L15 395 S BIOSIS L16 0 S L3 FILE 'BIOSIS' ENTERED AT 17:38:10 ON 26 JUN 2008

Updated Search

=> s 13

L17

0 L3